Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2019 3
2020 7
2021 3
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Modelling pharmacokinetics and pharmacodynamics of the selective S1P(1) receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients.
Lott D, Juif PE, Dingemanse J, Krause A. Lott D, et al. Br J Clin Pharmacol. 2020 Apr;86(4):791-800. doi: 10.1111/bcp.14182. Epub 2020 Jan 14. Br J Clin Pharmacol. 2020. PMID: 31756016 Free PMC article. Clinical Trial.
AIMS: Assessment of time to attain steady state as well as drug accumulation following long-term treatment with the selective sphingosine-1-phosphate 1 receptor modulator cenerimod and prediction of the incidence of low total lymphocyte (LY) counts. Differences in pharmaco …
AIMS: Assessment of time to attain steady state as well as drug accumulation following long-term treatment with the selective sphingosine-1- …
Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P(1) R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects.
Juif PE, Dingemanse J, Winkle P, Ufer M. Juif PE, et al. Clin Transl Sci. 2021 Jan;14(1):143-147. doi: 10.1111/cts.12873. Epub 2020 Sep 10. Clin Transl Sci. 2021. PMID: 32860737 Free PMC article. Clinical Trial.
Cenerimod is a sphingosine-1-phosphate 1 receptor (S1P(1) R) modulator in phase II development for treatment of systemic lupus erythematosus. ...In conclusion, the determined absence of any relevant PK or PD differences supports using the same doses of …
Cenerimod is a sphingosine-1-phosphate 1 receptor (S1P(1) R) modulator in phase II development for treatment of systemic lu …
Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P(1) receptor modulator in healthy subjects.
Boof ML, van Lier JJ, English S, Fischer H, Ufer M, Dingemanse J. Boof ML, et al. Xenobiotica. 2020 Aug;50(8):947-956. doi: 10.1080/00498254.2020.1736688. Epub 2020 Mar 9. Xenobiotica. 2020. PMID: 32105166
Cenerimod is a sphingosine-1-phosphate 1 receptor modulator under development for treatment of systemic lupus erythematosus.This single-centre, open-label, single-dose study investigated the mass balance and excretion routes and aimed at identifying an …
Cenerimod is a sphingosine-1-phosphate 1 receptor modulator under development for treatment of systemic lupus erythe …
Lack of Effect of Cenerimod, a Selective S1P(1) Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive.
Juif PE, Mueller MS, Charfi H, Dingemanse J. Juif PE, et al. Int J Mol Sci. 2022 Nov 29;23(23):14986. doi: 10.3390/ijms232314986. Int J Mol Sci. 2022. PMID: 36499313 Free PMC article. Clinical Trial.
Cenerimod, a sphingosine-1-phosphate 1 receptor modulator, is in development for the treatment of systemic lupus erythematosus, a disease mainly affecting women of childbearing potential. ...Overall, COC alone or in combination with cenerimod wa …
Cenerimod, a sphingosine-1-phosphate 1 receptor modulator, is in development for the treatment of systemic lupus ery …
Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus.
Strasser DS, Froidevaux S, Sippel V, Gerossier E, Grieder U, Pierlot GM, Kieninger-Graefitsch A, Vezzali E, Stalder AK, Renault B, Ryge J, Hart A, Mentzel U, Groenen PMA, Keller MP, Trendelenburg M, Martinic MM, Murphy MJ. Strasser DS, et al. RMD Open. 2020 Sep;6(2):e001261. doi: 10.1136/rmdopen-2020-001261. RMD Open. 2020. PMID: 32917831 Free PMC article.
METHODS: Cenerimod effect on lymphocyte numbers, organ pathology, inflammation, and survival was evaluated in the MRL/lpr lupus mouse model. ...CONCLUSION: Cenerimod significantly ameliorated systemic and organ-specific pathology and inflammation in a …
METHODS: Cenerimod effect on lymphocyte numbers, organ pathology, inflammation, and survival was evaluated in the MRL/lpr lupus …
Cenerimod, a selective S1P(1) receptor modulator, improves organ-specific disease outcomes in animal models of Sjogren's syndrome.
Gerossier E, Nayar S, Froidevaux S, Smith CG, Runser C, Iannizzotto V, Vezzali E, Pierlot G, Mentzel U, Murphy MJ, Martinic MM, Barone F. Gerossier E, et al. Arthritis Res Ther. 2021 Nov 29;23(1):289. doi: 10.1186/s13075-021-02673-x. Arthritis Res Ther. 2021. PMID: 34839819 Free PMC article.
Based on the mechanism of action of cenerimod, its efficacy was evaluated in two mouse models of Sjogren's syndrome. ...The effects of cenerimod treatment were then evaluated by flow cytometry, immunohistochemistry, histopathology and immunoassays. ...
Based on the mechanism of action of cenerimod, its efficacy was evaluated in two mouse models of Sjogren's syndrome. ...The effects o …
Attenuation of murine sclerodermatous models by the selective S1P(1) receptor modulator cenerimod.
Kano M, Kobayashi T, Date M, Tennichi M, Hamaguchi Y, Strasser DS, Takehara K, Matsushita T. Kano M, et al. Sci Rep. 2019 Jan 24;9(1):658. doi: 10.1038/s41598-018-37074-9. Sci Rep. 2019. PMID: 30679645 Free PMC article.
Bleomycin-induced SSc model mice were administered cenerimod from day 0 to 28. Early cenerimod administration inhibited, and delayed cenerimod administration attenuated skin and lung fibrosis in Scl-cGVHD mice. ...Furthermore, cenerimod attenuated bleo …
Bleomycin-induced SSc model mice were administered cenerimod from day 0 to 28. Early cenerimod administration inhibited, and d …
Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P1 Receptor Modulator in Healthy Subjects.
Juif PE, Baldoni D, Reyes M, Wilbraham D, Febbraro S, Vaclavkova A, Hoch M, Dingemanse J. Juif PE, et al. Int J Mol Sci. 2017 Dec 6;18(12):2636. doi: 10.3390/ijms18122636. Int J Mol Sci. 2017. PMID: 29211013 Free PMC article. Clinical Trial.
The pharmacokinetics, pharmacodynamics, tolerability, and food effect of cenerimod, a potent sphingosine-1-phosphate subtype 1 receptor modulator, were investigated in three sub-studies. ...Food had no relevant effect on the pharmacokinetics of cenerimod. A dose-dep …
The pharmacokinetics, pharmacodynamics, tolerability, and food effect of cenerimod, a potent sphingosine-1-phosphate subtype 1 recept …
Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects.
Juif PE, Ufer M, Dingemanse J. Juif PE, et al. Int J Mol Sci. 2019 Jul 1;20(13):3232. doi: 10.3390/ijms20133232. Int J Mol Sci. 2019. PMID: 31266149 Free PMC article.
Active treatment consisted of a single dose of 10 mg ponesimod on Day 1, 18, and 37 and multiple-dose administration of 2 mg once daily cenerimod (Day 9-36). Placebos of cenerimod and ponesimod were used as reference treatment. ...Treatment with ponesimod and cen …
Active treatment consisted of a single dose of 10 mg ponesimod on Day 1, 18, and 37 and multiple-dose administration of 2 mg once daily c …
Estimation of Attainment of Steady-State Conditions for Compounds With a Long Half-Life.
Krause A, Lott D, Dingemanse J. Krause A, et al. J Clin Pharmacol. 2021 Jan;61(1):82-89. doi: 10.1002/jcph.1701. Epub 2020 Jul 12. J Clin Pharmacol. 2021. PMID: 32656870 Review.
The relevance of accurate estimation of time to attainment of steady state is illustrated with cenerimod, an sphingosine-1-phosphate 1 receptor modulator with long half-life currently in clinical development for which estimates of time to steady state ranged from 35 to 110 …
The relevance of accurate estimation of time to attainment of steady state is illustrated with cenerimod, an sphingosine-1-phosphate …
16 results